BR112015020222A8 - composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas - Google Patents
composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticasInfo
- Publication number
- BR112015020222A8 BR112015020222A8 BR112015020222A BR112015020222A BR112015020222A8 BR 112015020222 A8 BR112015020222 A8 BR 112015020222A8 BR 112015020222 A BR112015020222 A BR 112015020222A BR 112015020222 A BR112015020222 A BR 112015020222A BR 112015020222 A8 BR112015020222 A8 BR 112015020222A8
- Authority
- BR
- Brazil
- Prior art keywords
- azetidinyloxyphenylpyrrolidine
- compound
- pharmaceutical compositions
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
resumo patente de invenção: "compostos de azetidiniloxifenilpirrolidina". a invenção refere-se a certos compostos de azetidiniloxifenilpirrolidina, particularmente compostos de fórmula i i em que r é hidrogênio ou metila, e composições farmacêuticas destes. a invenção refere-se adicionalmente a métodos para o uso de um composto de fórmula i para tratar bexiga hiperativa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361778546P | 2013-03-13 | 2013-03-13 | |
US61/778,546 | 2013-03-13 | ||
PCT/US2014/021474 WO2014159012A1 (en) | 2013-03-13 | 2014-03-07 | Azetidinyloxyphenylpyrrolidine compounds |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112015020222A2 BR112015020222A2 (pt) | 2017-07-18 |
BR112015020222A8 true BR112015020222A8 (pt) | 2018-01-23 |
BR112015020222B1 BR112015020222B1 (pt) | 2020-07-14 |
Family
ID=50382705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015020222-5A BR112015020222B1 (pt) | 2013-03-13 | 2014-03-07 | Azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas |
Country Status (40)
Country | Link |
---|---|
US (3) | US9034864B2 (pt) |
EP (2) | EP2970222B1 (pt) |
JP (2) | JP6017708B2 (pt) |
KR (2) | KR101702797B1 (pt) |
CN (2) | CN109336865A (pt) |
AP (1) | AP3850A (pt) |
AR (1) | AR095015A1 (pt) |
AU (1) | AU2014241444B2 (pt) |
BR (1) | BR112015020222B1 (pt) |
CA (1) | CA2899806C (pt) |
CL (1) | CL2015002113A1 (pt) |
CR (1) | CR20150417A (pt) |
CY (1) | CY1120142T1 (pt) |
DK (1) | DK2970222T3 (pt) |
DO (1) | DOP2015000176A (pt) |
EA (1) | EA026631B1 (pt) |
ES (1) | ES2616470T3 (pt) |
HK (1) | HK1212695A1 (pt) |
HR (1) | HRP20170080T1 (pt) |
HU (1) | HUE032235T2 (pt) |
IL (1) | IL240904B (pt) |
JO (1) | JO3264B1 (pt) |
LT (1) | LT2970222T (pt) |
MA (1) | MA38410B1 (pt) |
ME (1) | ME02592B (pt) |
MX (1) | MX2015012579A (pt) |
MY (1) | MY180006A (pt) |
NZ (1) | NZ710481A (pt) |
PE (1) | PE20151669A1 (pt) |
PH (1) | PH12015502032A1 (pt) |
PL (1) | PL2970222T3 (pt) |
PT (1) | PT2970222T (pt) |
RS (1) | RS55594B1 (pt) |
SG (2) | SG10201609717YA (pt) |
SI (1) | SI2970222T1 (pt) |
TN (1) | TN2015000384A1 (pt) |
TW (1) | TWI617553B (pt) |
UA (1) | UA115583C2 (pt) |
WO (1) | WO2014159012A1 (pt) |
ZA (1) | ZA201505417B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
WO2016033776A1 (en) * | 2014-09-04 | 2016-03-10 | Eli Lilly And Company | Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol |
TW201625591A (zh) * | 2014-09-12 | 2016-07-16 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
EP3901146A4 (en) * | 2018-12-18 | 2022-01-19 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | PHENYLPYRROLIDINE COMPOUND AND USE THEREOF |
CN111333625B (zh) * | 2018-12-18 | 2022-10-18 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类化合物及其用途 |
CN111333637B (zh) * | 2018-12-18 | 2022-07-29 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类衍生物及其制备方法 |
CN112409333A (zh) * | 2019-08-23 | 2021-02-26 | 湖北生物医药产业技术研究院有限公司 | 苯基吡咯烷类化合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665754A (en) * | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
JPH07300455A (ja) * | 1994-03-08 | 1995-11-14 | Mitsubishi Chem Corp | 3−フェニルピロリジン誘導体 |
DE19601938A1 (de) * | 1996-01-12 | 1997-07-17 | Schering Ag | Neue Phosphodiesteraseinhibitoren |
US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
US6258833B1 (en) | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
PL365443A1 (en) * | 2001-01-31 | 2005-01-10 | Pfizer Products Inc. | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes |
WO2007039075A2 (en) | 2005-09-29 | 2007-04-12 | Bayer Healthcare Ag | Pde inhibitors and combinations thereof for the treatment of urological disorders |
TW201206440A (en) | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
EP2569302A1 (en) | 2010-05-13 | 2013-03-20 | Amgen, Inc | Heteroaryloxyheterocyclyl compounds as pde10 inhibitors |
TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
-
2014
- 2014-03-04 TW TW103107294A patent/TWI617553B/zh active
- 2014-03-04 JO JOP/2014/0068A patent/JO3264B1/ar active
- 2014-03-05 AR ARP140100712A patent/AR095015A1/es active IP Right Grant
- 2014-03-07 CN CN201811189530.XA patent/CN109336865A/zh active Pending
- 2014-03-07 SI SI201430124A patent/SI2970222T1/sl unknown
- 2014-03-07 PL PL14712968T patent/PL2970222T3/pl unknown
- 2014-03-07 US US14/200,376 patent/US9034864B2/en active Active
- 2014-03-07 KR KR1020157024606A patent/KR101702797B1/ko active Application Filing
- 2014-03-07 AU AU2014241444A patent/AU2014241444B2/en active Active
- 2014-03-07 KR KR1020177002304A patent/KR101745304B1/ko active IP Right Grant
- 2014-03-07 EP EP14712968.8A patent/EP2970222B1/en active Active
- 2014-03-07 CA CA2899806A patent/CA2899806C/en active Active
- 2014-03-07 SG SG10201609717YA patent/SG10201609717YA/en unknown
- 2014-03-07 CN CN201480014091.2A patent/CN105051034B/zh active Active
- 2014-03-07 DK DK14712968.8T patent/DK2970222T3/en active
- 2014-03-07 JP JP2015561688A patent/JP6017708B2/ja active Active
- 2014-03-07 UA UAA201508671A patent/UA115583C2/uk unknown
- 2014-03-07 MY MYPI2015703060A patent/MY180006A/en unknown
- 2014-03-07 PT PT147129688T patent/PT2970222T/pt unknown
- 2014-03-07 SG SG11201507501YA patent/SG11201507501YA/en unknown
- 2014-03-07 PE PE2015001904A patent/PE20151669A1/es active IP Right Grant
- 2014-03-07 BR BR112015020222-5A patent/BR112015020222B1/pt active IP Right Grant
- 2014-03-07 EP EP16196721.1A patent/EP3168216A1/en not_active Withdrawn
- 2014-03-07 ME MEP-2017-10A patent/ME02592B/me unknown
- 2014-03-07 WO PCT/US2014/021474 patent/WO2014159012A1/en active Application Filing
- 2014-03-07 HU HUE14712968A patent/HUE032235T2/en unknown
- 2014-03-07 RS RS20170035A patent/RS55594B1/sr unknown
- 2014-03-07 LT LTEP14712968.8T patent/LT2970222T/lt unknown
- 2014-03-07 MA MA38410A patent/MA38410B1/fr unknown
- 2014-03-07 ES ES14712968.8T patent/ES2616470T3/es active Active
- 2014-03-07 NZ NZ710481A patent/NZ710481A/en unknown
- 2014-03-07 AP AP2015008699A patent/AP3850A/en active
- 2014-03-07 EA EA201591498A patent/EA026631B1/ru not_active IP Right Cessation
- 2014-03-07 MX MX2015012579A patent/MX2015012579A/es active IP Right Grant
-
2015
- 2015-01-13 US US14/595,262 patent/US9266859B2/en active Active
- 2015-07-24 DO DO2015000176A patent/DOP2015000176A/es unknown
- 2015-07-28 ZA ZA2015/05417A patent/ZA201505417B/en unknown
- 2015-07-29 CL CL2015002113A patent/CL2015002113A1/es unknown
- 2015-08-14 CR CR20150417A patent/CR20150417A/es unknown
- 2015-08-27 IL IL240904A patent/IL240904B/en active IP Right Grant
- 2015-09-03 TN TN2015000384A patent/TN2015000384A1/en unknown
- 2015-09-10 PH PH12015502032A patent/PH12015502032A1/en unknown
-
2016
- 2016-01-15 US US14/996,321 patent/US9604967B2/en active Active
- 2016-01-21 HK HK16100630.8A patent/HK1212695A1/zh unknown
- 2016-09-28 JP JP2016189812A patent/JP6204557B2/ja active Active
-
2017
- 2017-01-18 HR HRP20170080TT patent/HRP20170080T1/hr unknown
- 2017-02-03 CY CY20171100164T patent/CY1120142T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
BR112015020222A8 (pt) | composto de azetidiniloxifenilpirrolidina, seus usos, e composições farmacêuticas | |
BR112017002053A2 (pt) | composto de acordo com a fórmula (i), composição farmacêutica, e usos de um composto | |
DOP2016000085A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
BR112015022191A2 (pt) | compostos heteroarila, seu uso e composição que os compreende | |
CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
DK2970216T3 (da) | Biarylamidforbindelser som kinaseinhibitorer | |
BR112017002214A2 (pt) | composto de fórmula (i), composição farmacêutica e usos de um composto | |
BR112015021352A2 (pt) | composições antimicrobianas | |
BR112015024530A8 (pt) | compostos derivados de naftiridina úteis como antagonistas de integrina alfa-v-beta-6, composição farmacêutica, e, uso de um composto | |
BR112015019276A2 (pt) | compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios | |
BR112016007427A2 (pt) | compostos de pirazol-amida e usos dos mesmos | |
BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica | |
BR112012024822B8 (pt) | Composto, uso de um composto e composição farmacêutica | |
BR112015012825A2 (pt) | piridopirazinas substituídas como inibidores de syk | |
BR112014007078A2 (pt) | composição de controle de doença de plantas e seu uso | |
BR112015004523A2 (pt) | compostos de tetraciclina | |
BR112015024075A2 (pt) | compostos de piridinilpirazoloquinolina | |
MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
BR112016008704A8 (pt) | derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos | |
BR112015030589A8 (pt) | formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas | |
BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
BR112015022970A2 (pt) | composição farmacêutica de cloridrato de s-cetamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |